Antibody avidity-based approach to estimate population-level incidence of hepatitis C.

ABSTRACT:

Background & aims

Accurate HCV incidence estimates are critical for monitoring progress towards HCV elimination goals, including an 80% reduction in HCV incidence by 2030. Moreover, incidence estimates can help guide prevention and treatment programming, particularly in the context of the US opioid epidemic.

Methods

An inexpensive, Genedia-based HCV IgG antibody avidity assay was evaluated as a platform to estimate cross-sectional, population-level primary HCV incidence using 1,840 HCV antibody and RNA-positive samples from 875 individuals enrolled in 5 cohort studies in the US and India. Using samples collected <2 years following HCV seroconversion, the mean duration of recent infection (MDRI) was calculated by fitting a maximum likelihood binomial regression model to the p

SUBMITTER: Boon D 

PROVIDER: S-EPMC7458132 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature